



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

***iLite*[®] IFN beta 1a NAb positive control**

REF: BM3251

For research use only. Not for use in diagnostic procedures.

DESCRIPTION

iLite[®] IFN beta 1a NAb positive control is a polyclonal rabbit antibody with a neutralizing effect on IFN beta 1a and can be used together with *iLite*[®] Type I IFN Assay Ready Cells (BM3049).

CONTENT

45 µL of *iLite*[®] IFN beta 1a NAb positive control diluted in RPMI 1640 with 10% heat inactivated fetal bovine serum (FBS) and 1% Penicillin Streptomycin.

RECEIPT AND STORAGE

Upon receipt confirm that adequate dry-ice is present, and the cells are frozen. Immediately transfer to -80°C storage. Cells should be stored at -80°C (**do not store at any other temperature**) and are stable as supplied until the expiry date shown. Cells should be used within 30 min of thawing.

BACKGROUND

Interferon beta (IFNβ) is well established as first line therapy in relapsing/remitting multiple sclerosis. The occurrence of NAb and binding antibodies (BAbs) to IFNβ has been widely reported. Subjects with NAb have shown reduced response to treatment with IFNβ, having higher relapse rates, increased MRI activity and higher risk of disease progression. The frequencies and titers of NAb vary depending on the preparation used, dose and frequency of administration and also the assay used to quantify them.

APPLICATION

The *iLite*[®] IFN beta 1a NAb positive control can be used as positive control for neutralizing antibodies against IFN when using *iLite* Type I IFN Assay Ready Cells (BM3049).

Application Notes for the following assays are available:

- Measurement of anti-IFN α or β antibodies (NAb) (LABEL-DOC-0387)

RELATED PRODUCTS

REF	Product name
BM3049	<i>iLite</i> [®] Type I IFN Assay Ready Cells
BM3250	<i>iLite</i> [®] Diluent D
BM3249	<i>iLite</i> [®] IFN beta 1a (950 IU/mL)

REFERENCES

1. Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen PS, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, Fogdell-Hahn A, on behalf of the ABIRISK consortium: *Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta*. J Immunol Methods, 430: 1-9 (2016)

SYMBOLS ON LABEL

	Lot number		Temperature limitation
	Catalogue number		Biological risk
	Use by		Manufacturer

PRECAUTIONS

For research use only. This product is intended for professional laboratory research use only. The data and results originating from using the product, should not be used either in diagnostic procedures or in human therapeutic applications.

The product contains human/bovine serum and if human serum is analysed it should be handled as if capable of transmitting infectious agents.

Residues of chemicals and preparations generally considered as biohazardous waste and should be inactivated prior to disposal by autoclaving or using bleach. All such materials should be disposed of in accordance with established safety procedures.

PROPRIETARY INFORMATION

In accepting delivery of *iLite*[®] Assay Ready Cells the recipient agrees not to sub-culture these cells, attempt to sub-culture them or to give them to a third party, and only to use them directly in assays. *iLite*[®] cell-based products are covered by patents which is the property of Svar Life Science AB and any attempt to reproduce the delivered *iLite*[®] Assay Ready Cells is an infringement of these patents.